NLRP3 and Hepatic fibrosis: In an in vivo study, Gong et al. reported that inhibition of NLRP3 inflammasomes by Caspase-1 inhibitors significantly reduced IL-1β levels in liver tissues of mice, thereby ameliorating the effects of liver injury induced by hepatic fibrosis [45].